Explore chapters and articles related to this topic
Systemic Lupus Erythematosus
Published in Jason Liebowitz, Philip Seo, David Hellmann, Michael Zeide, Clinical Innovation in Rheumatology, 2023
Vaneet K. Sandhu, Neha V. Chiruvolu, Daniel J. Wallace
Proteomics or target protein arrays may be helpful in identifying biomarkers for early renal involvement in SLE. Given the paucity of noninvasive renal biomarkers to identify early disease, use of proteomic assays opens up the possibility of establishing potential lupus nephritis (LN) biomarkers. For example, renal tubulointerstitial fibrosis portends increased risk for renal failure, and its identification has traditionally required a renal biopsy. However, a recent study analyzing urinary peptides for thirty-six patients with lupus nephritis and thirty-five patients with nonrenal SLE has identified 70 collagen and 230 noncollagen peptides that may serve as biomarkers for renal progression.13 In a large study of patients with LN, screening for 274 biomarker proteins using targeted protein array identified AXL, FAS, ferritin, IGFBP2, Siglec5, and sTNFRII as highly correlated with a combination of either SLE disease activity index (SLEDAI), eGFR, serum creatinine, and/or renal pathology activity indices. The intention is for these biomarkers to be “predictive” for disease flare and be used in monitoring disease progression and treatment.14
Biologics for chronic spontaneous urticaria: toward a personalized treatment
Published in Expert Review of Clinical Immunology, 2022
Riccardo Asero, Silvia Ferrucci, Alberto Tedeschi, Massimo Cugno
Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a glycan-binding inhibitory receptor selectively expressed on eosinophils and mast cells. Lirentelimab, an anti-Siglec-8 mAb, was tested in patients with chronic spontaneous or inducible urticaria. The drug induced an increase in urticaria control test in the whole study group but, in CSU patients, the effect was much better in omalizumab-naïve patients (complete response rate 92%) than in omalizumab-refractory ones (36% complete response rate) [57].
Endotype-driven precision medicine in chronic rhinosinusitis
Published in Expert Review of Clinical Immunology, 2019
Hongfei Lou, Chengshuo Wang, Luo Zhang
Siglec-8 is a cell surface receptor that is uniquely expressed by human eosinophils, mast cells, and basophils [83]. The activation of siglec-8 induces antibody-dependent cell-mediated cytotoxicity (ADCC) activities [121], and lead to apoptotic cell death in eosinophils. A phase 2 trial of siglec-8 for patients with CRSwNP (NCT02734849) is underway.